Factors affecting clinical decision making in refractory and relapsed CP-CML patients
Delphine Réa, Centre Hospitalo-Universitaire Saint-Louis, Paris, France

• TKI resistance: significance and definition 
• BCR-ABL1 mutations and resistance to imatinib and 2nd generation TKI's
• Failure of 1st and 2nd generation TKI's
• Mortality and causes of death in CP-CML patients during 2nd or subsequent line TKI
• Responses to 3rd line therapy after resistance or intolerance to 2nd generation TKI
• 5-year results from the PACE study: Responses to ponatinib in CP-CML patients
• Therapeutic innovation: allosteric inhibition of BCR-ABL1 by ABL001
• Conclusion and perspective

This presentation is adapted from one given during the industry sponsored symposium at EHA.